Silo Pharma, Inc. (SILO)
$2.48-$0.06 (-2.36%) Today
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
No Form 4 activity for SILO in the last 90 days.
5 Form 4 filings on record, the earliest from Nov 22, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Eric Weisblum - Officer | Open-market purchase | Common Stock | 2,500 | $6.15 | $1K | |
| Eric Weisblum - Officer | Open-market purchase | Common Stock | 2,500 | $6.30 | $1K | |
| Eric Weisblum - Officer | Open-market purchase | Common Stock | 1,000 | $5.55 | $370 | |
| Eric Weisblum - Officer | Open-market purchase | Common Stock | 1,000 | $5.48 | $365 | |
| Eric Weisblum - Officer | Open-market purchase | Common Stock | 7,500 | $6.05 | $3K | |
| Eric Weisblum - Officer | Open-market purchase | Common Stock | 4,500 | $6.08 | $2K | |
| Eric Weisblum - Officer | Open-market purchase | Common Stock | 2,500 | $12.58 | $2K | |
| Eric Weisblum - Officer | Open-market purchase | Common Stock | 2,500 | $14.25 | $2K | |
| Eric Weisblum - Officer | Open-market purchase | Common Stock | 2,500 | $13.50 | $2K |
Silo Pharma, Inc. (SILO) has filed no insider reports in the last 90 days. The most recent on record is dated 2025-12-16. The full record for SILO runs to 5 Form 4 filings, the earliest from 2024-11-22. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of SILO were filed in the last 90 days. 9 purchases are on record for this company.
No insider sales of SILO were filed in the last 90 days.
This page tracks SILO Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add SILO to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
